Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence

Expert Opinion on Drug Safety

Volumn 14, Issue 3, 2015, Pages 413-427

  Weisskopf, Etienne ^a   Fischer, Céline J ^b   Bickle Graz, Myriam ^b   Morisod Harari, Mathilde ^b   Tolsa, Jean François ^b   Claris, Olivier ^c   Vial, Yvan ^b   Eap, Chin B ^b   Csajka, Chantal ^a,b   Panchaud, Alice ^a,b  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c HOSPICES CIVILS DE LYON   (France)

Author keywords

Antidepressant; Benefit; Lactation; Pregnancy; Risk; Selective serotonin reuptake inhibitors

Indexed keywords

ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR;

BIRTH DEFECT; BREAST FEEDING; DRUG SAFETY; DRUG USE; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; LACTATION; LOW BIRTH WEIGHT; MAJOR DEPRESSION; MOTHER CHILD RELATION; PERSISTENT PULMONARY HYPERTENSION; PREECLAMPSIA; PREGNANCY; PREMATURE LABOR; REVIEW; RISK BENEFIT ANALYSIS; SPONTANEOUS ABORTION; DEPRESSIVE DISORDER; PREGNANCY COMPLICATIONS; PUERPERIUM;

DEPRESSIVE DISORDER; FEMALE; HUMANS; LACTATION; POSTPARTUM PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS; SEROTONIN UPTAKE INHIBITORS;

EID: 84923339560     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2015.997708     Document Type: Review

References (122)

1. Data and statistics: prevalence of mental disorders. World Health Organisation. WHO Regional Office for Europe. 2014. Available from: http://www.euro. who.int/en/what-we-do/health-topics/ noncommunicable-diseases/mental-health/ facts-and-figures [Last accessed 4 July 2014]
2. Gavin NI, Gaynes BN, Lohr KN, et al. Perinatal depression: a systematic review of prevalence and incidence. Obstet Gynecol 2005;106:1071-83
3. Mitchell AA, Gilboa SM, Werler MM, et al. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol 2011;205:51.e1-8
4. OCEBM Levels of Evidence, 2011. Available from: http://www.cebm.net/ ocebm-levels-of-evidence/ [Last accessed 8 September 2014]
5. Atkins D, Eccles M, Flottorp S, et al. Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group. BMC Health Serv Res 2004;4:38
6. Barr JA, Beck CT. Infanticide secrets: qualitative study on postpartum depression. Can Fam Physician 2008;54:1716-1717.e5
7. Kauppi A, Kumpulainen K, Vanamo T, et al. Maternal depression and filicidecase study of ten mothers. Arch Womens Ment Health 2008;11:201-6
8. Howard LM, Flach C, Mehay A, et al. The prevalence of suicidal ideation identified by the Edinburgh Postnatal Depression Scale in postpartum women in primary care: findings from the RESPOND trial. BMC Pregnancy Childbirth 2011;11:57
9. Lindahl V, Pearson JL, Colpe L. Prevalence of suicidality during pregnancy and the postpartum. Arch Womens Ment Health 2005;8:77-87
10. Pope CJ, Xie B, Sharma V, Campbell MK. A prospective study of thoughts of self-harm and suicidal ideation during the postpartum period in women with mood disorders. Arch Womens Ment Health 2013;16:483-8
11. Pajulo M, Savonlahti E, Sourander A, et al. Antenatal depression, substance dependency and social support. J Affect Disord 2001;65:9-17
12. Zuckerman B, Amaro H, Bauchner H, Cabral H. Depressive symptoms during pregnancy: relationship to poor health behaviors. Am J Obstet Gynecol 1989;160:1107-11
13. Connelly CD, Hazen AL, Baker-Ericzen MJ, et al. Is screening for depression in the perinatal period enough? The cooccurrence of depression, substance abuse, and intimate partner violence in culturally diverse pregnant women. J Womens Health (Larchmt) 2013;22:844-52
14. Flynn HA, Chermack ST. Prenatal alcohol use: the role of lifetime problems with alcohol, drugs, depression, and violence. J Stud Alcohol Drugs 2008;69:500-9
15. Alberque C, Bianchi-Demicheli F, Andreoli A, et al. [Management of severe antepartum depression: an update]. Rev Med Suisse 2008;4:392, 394, 396-7
16. Grote NK, Bridge JA, Gavin AR, et al. A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. Arch Gen Psychiatry 2010;67:1012-24
17. Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. The impact of maternal depression during pregnancy on perinatal outcomes: a systematic review and meta-analysis. J Clin Psychiatry 2013;74:e321-41
18. Nelson DB, McMahon K, Joffe M, Brensinger C. The effect of depressive symptoms and optimism on the risk of spontaneous abortion among innercity women. J Womens Health (Larchmt) 2003;12:569-76
19. Sugiura-Ogasawara M, Furukawa TA, Nakano Y, et al. Depression as a potential causal factor in subsequent miscarriage in recurrent spontaneous aborters. Hum Reprod 2002;17:2580-4
20. Deave T, Heron J, Evans J, Emond A. The impact of maternal depression in pregnancy on early child development. BJOG 2008;115:1043-51
21. Austin MP, Hadzi-Pavlovic D, Leader L, et al. Maternal trait anxiety, depression and life event stress in pregnancy: relationships with infant temperament. Early Hum Dev 2005;81:183-90
22. Barker ED, Jaffee SR, Uher R, Maughan B. The contribution of prenatal and postnatal maternal anxiety and depression to child maladjustment. Depress Anxiety 2011;28:696-702
23. Luoma I, Tamminen T, Kaukonen P, et al. Longitudinal study of maternal depressive symptoms and child wellbeing. J Am Acad Child Adolesc Psychiatry 2001;40:1367-74
24. Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition. American Psychiatry Association Practice Guidelines. 2010. Available from: http:// psychiatryonline.org/content. aspx?bookID=28§ionID= 1667485#654269 [Last accessed 4 July 2014]
25. CG90 Depression in adults: the treatment and management of depression in adults. NICE clinical guidelines. 2009. Available from: http://publications. nice.org.uk/depression-in-adults-cg90/ guidance [Last accessed 4 July 2014]
26. Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: a patient-level metaanalysis. JAMA 2010;303:47-53
27. Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008;5:e45
28. Sockol LE, Epperson CN, Barber JP. A meta-analysis of treatments for perinatal depression. Clin Psychol Rev 2011;31:839-49
29. Cuijpers P, Andersson G, Donker T, van Straten A. Psychological treatment of depression: results of a series of metaanalyses. Nord J Psychiatry 2011;65:354-64
30. Claridge AM. Efficacy of systemically oriented psychotherapies in the treatment of perinatal depression: a meta-analysis. Arch Womens Ment Health 2014;17:3-15
31. Dennis CL, Ross LE, Grigoriadis S. Psychosocial and psychological interventions for treating antenatal depression. Cochrane Database Syst Rev 2007;CD006309
32. Muzik M, Hamilton SE, Lisa Rosenblum K, et al. Mindfulness yoga during pregnancy for psychiatrically at-risk women: preliminary results from a pilot feasibility study. Complement Ther Clin Pract 2012;18:235-40
33. Dennis CL, Dowswell T. Interventions (other than pharmacological, psychosocial or psychological) for treating antenatal depression. Cochrane Database Syst Rev 2013;7:CD006795
34. Field T, Deeds O, Diego M, et al. Benefits of combining massage therapy with group interpersonal psychotherapy in prenatally depressed women. J Bodyw Mov Ther 2009;13:297-303
35. Manber R, Schnyer RN, Lyell D, et al. Acupuncture for depression during pregnancy: a randomized controlled trial. Obstet Gynecol 2010;115:511-20
36. Freeman MP, Davis M, Sinha P, et al. Omega-3 fatty acids and supportive psychotherapy for perinatal depression: a randomized placebo-controlled study. J Affect Disord 2008;110:142-8
37. Wirz-Justice A, Bader A, Frisch U, et al. A randomized, double-blind, placebocontrolled study of light therapy for antepartum depression. J Clin Psychiatry 2011;72:986-93
38. Wisner KL, Perel JM, Peindl KS, et al. Prevention of postpartum depression: a pilot randomized clinical trial. Am J Psychiatry 2004;161:1290-2
39. Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006;295:499-507
40. Yonkers KA, Gotman N, Smith MV, et al. Does antidepressant use attenuate the risk of a major depressive episode in pregnancy? Epidemiology 2011;22:848-54
41. Panchaud A, Weisskopf E, Winterfeld U, et al. Médicaments et grossesse : modifications pharmacocinétiques et place du suivi thérapeutique pharmacologique. Thérapie 2014;69(3):223-34
42. Heikkinen T, Ekblad U, Kero P, et al. Citalopram in pregnancy and lactation. Clin Pharmacol Ther 2002;72:184-91
43. Freeman MP, Nolan PE Jr, Davis MF, et al. Pharmacokinetics of sertraline across pregnancy and postpartum. J Clin Psychopharmacol 2008;28:646-53
44. Heikkinen T, Ekblad U, Palo P, Laine K. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clin Pharmacol Ther 2003;73:330-7
45. Sit DK, Perel JM, Helsel JC, Wisner KL. Changes in antidepressant metabolism and dosing across pregnancy and early postpartum. J Clin Psychiatry 2008;69:652-8
46. Hanley GE, Mintzes B. Patterns of psychotropic medicine use in pregnancy in the United States from 2006 to 2011 among women with private insurance. BMC Pregnancy Childbirth 2014;14:242
47. Hendrick V, Stowe ZN, Altshuler LL, et al. Placental passage of antidepressant medications. Am J Psychiatry 2003;160:993-6
48. Rampono J, Simmer K, Ilett KF, et al. Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. Pharmacopsychiatry 2009;42:95-100
49. Hemels ME, Einarson A, Koren G, et al. Antidepressant use during pregnancy and the rates of spontaneous abortions: a meta-analysis. Ann Pharmacother 2005;39:803-9
50. Nikfar S, Rahimi R, Hendoiee N, Abdollahi M. Increasing the risk of spontaneous abortion and major malformations in newborns following use of serotonin reuptake inhibitors during pregnancy: a systematic review and updated meta-analysis. Daru 2012;20:75
51. Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. Antidepressant exposure during pregnancy and congenital malformations: is there an association? A systematic review and meta-analysis of the best evidence. J Clin Psychiatry 2013;74:e293-308
52. Bar-Oz B, Einarson T, Einarson A, et al. Paroxetine and congenital malformations: meta-Analysis and consideration of potential confounding factors. Clin Ther 2007;29:918-26
53. Wurst KE, Poole C, Ephross SA, Olshan AF. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol 2010;88:159-70
54. Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol 2002;39:1890-900
55. Riggin L, Frankel Z, Moretti M, et al. The fetal safety of fluoxetine: a systematic review and meta-analysis. J Obstet Gynaecol Can 2013;35:362-9
56. Jimenez-Solem E, Andersen JT, Petersen M, et al. Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study. BMJ Open 2012;2:e001148. doi:10. 1136/bmjopen-2012-001148
57. Huybrechts KF, Palmsten K, Avorn J, et al. Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med 2014;370:2397-407
58. Palmsten K, Huybrechts KF, Michels KB, et al. Antidepressant use and risk for preeclampsia. Epidemiology 2013;24:682-91
59. Palmsten K, Setoguchi S, Margulis AV, et al. Elevated risk of preeclampsia in pregnant women with depression: depression or antidepressants? Am J Epidemiol 2012;175:988-97
60. Palmsten K, Hernandez-Diaz S, Huybrechts KF, et al. Use of antidepressants near delivery and risk of postpartum hemorrhage: cohort study of low income women in the United States. BMJ 2013;347:f4877
61. Lupattelli A, Spigset O, Koren G, Nordeng H. Risk of vaginal bleeding and postpartum hemorrhage after use of antidepressants in pregnancy: a study from the Norwegian Mother and Child Cohort Study. J Clin Psychopharmacol 2014;34:143-8
62. Salkeld E, Ferris LE, Juurlink DN. The risk of postpartum hemorrhage with selective serotonin reuptake inhibitors and other antidepressants. J Clin Psychopharmacol 2008;28:230-4
63. Huang H, Coleman S, Bridge JA, et al. A meta-analysis of the relationship between antidepressant use in pregnancy and the risk of preterm birth and low birth weight. Gen Hosp Psychiatry 2014;36:13-18
64. Huybrechts KF, Sanghani RS, Avorn J, Urato AC. Preterm birth and antidepressant medication use during pregnancy: a systematic review and metaanalysis. PLoS One 2014;9:e92778
65. Ross LE, Grigoriadis S, Mamisashvili L, et al. Selected pregnancy and delivery outcomes after exposure to antidepressant medication: a systematic review and meta-analysis. JAMA Psychiatry 2013;70:436-43
66. Levinson-Castiel R, Merlob P, Linder N, et al. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 2006;160:173-6
67. Leibovitch L, Rymer-Haskel N, Schushan-Eisen I, et al. Short-term neonatal outcome among term infants after in utero exposure to serotonin reuptake inhibitors. Neonatology 2013;104:65-70
68. Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005;293:2372-83
69. Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. The effect of prenatal antidepressant exposure on neonatal adaptation: a systematic review and meta-analysis. J Clin Psychiatry 2013;74:e309-20
70. Lund N, Pedersen LH, Henriksen TB. Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes. Arch Pediatr Adolesc Med 2009;163:949-54
71. Grzeskowiak LE, Gilbert AL, Morrison JL. Neonatal outcomes after lategestation exposure to selective serotonin reuptake inhibitors. J Clin Psychopharmacol 2012;32:615-21
72. Malm H, Klaukka T, Neuvonen PJ. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol 2005;106:1289-96
73. Oberlander TF, Warburton W, Misri S, et al. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006;63:898-906
74. Kieviet N, Dolman KM, Honig A. The use of psychotropic medication during pregnancy: how about the newborn? Neuropsychiatr Dis Treat 2013;9:1257-66
75. Klinger G, Frankenthal D, Merlob P, et al. Long-term outcome following selective serotonin reuptake inhibitor induced neonatal abstinence syndrome. J Perinatol 2011;31:615-20
76. Warburton W, Hertzman C, Oberlander TF. A register study of the impact of stopping third trimester selective serotonin reuptake inhibitor exposure on neonatal health. Acta Psychiatr Scand 2010;121:471-9
77. Jensen HM, Gron R, Lidegaard O, et al. Maternal depression, antidepressant use in pregnancy and Apgar scores in infants. Br J Psychiatry 2013;202:347-51
78. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotoninreuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006;354:579-87
79. Kallen B, Olausson PO. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2008;17:801-6
80. Andrade SE, McPhillips H, Loren D, et al. Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2009;18:246-52
81. Wilson KL, Zelig CM, Harvey JP, et al. Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors. Am J Perinatol 2011;28:19-24
82. Kieler H, Artama M, Engeland A, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ 2012;344:d8012
83. Grigoriadis S, Vonderporten EH, Mamisashvili L, et al. Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and meta-analysis. BMJ 2014;348:f6932
84. Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants: drug Safety Communication - Use During Pregnancy and Potential Risk of Persistent Pulmonary Hypertension of the Newborn. FDA Safety Alerts. FDA Drug Safety Communication. 2011. Available from: http://www.fda. gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ ucm283696.htm [Last accessed 4 July 2014]
85. Gentile S, Galbally M. Prenatal exposure to antidepressant medications and neurodevelopmental outcomes: a systematic review. J Affect Disord 2011;128:1-9
86. Austin MP, Karatas JC, Mishra P, et al. Infant neurodevelopment following in utero exposure to antidepressant medication. Acta Paediatr 2013;102:1054-9
87. Grzeskowiak LE, Gilbert AL, Sorensen TI, et al. Prenatal exposure to selective serotonin reuptake inhibitors and childhood overweight at 7 years of age. Ann Epidemiol 2013;23:681-7
88. Grzeskowiak LE, Gilbert AL, Morrison JL. Prenatal exposure to selective serotonin reuptake inhibitors and risk of childhood overweight. J Dev Orig Health Dis 2012;3(4):253-61
89. Wisner KL, Bogen DL, Sit D, et al. Does fetal exposure to SSRIs or maternal depression impact infant growth? Am J Psychiatry 2013;170:485-93
90. Oberlander TF, Grunau RE, Fitzgerald C, et al. Pain reactivity in 2-month-old infants after prenatal and postnatal serotonin reuptake inhibitor medication exposure. Pediatrics 2005;115:411-25
91. de Vries NK, van der Veere CN, Reijneveld SA, Bos AF. Early neurological outcome of young infants exposed to selective serotonin reuptake inhibitors during pregnancy: results from the observational SMOK study. PLoS One 2013;8:e64654
92. Casper RC, Fleisher BE, Lee-Ancajas JC, et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 2003;142:402-8
93. Hanley GE, Brain U, Oberlander TF. Infant developmental outcomes following prenatal exposure to antidepressants, and maternal depressed mood and positive affect. Early Hum Dev 2013;89:519-24
94. Nulman I, Koren G, Rovet J, et al. Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression. Am J Psychiatry 2012;169:1165-74
95. Skurtveit S, Selmer R, Roth C, et al. Prenatal exposure to antidepressants and language competence at age three: results from a large population-based pregnancy cohort in Norway. BJOG 2014;121(13):1621-31
96. Croen LA, Grether JK, Yoshida CK, et al. Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry 2011;68:1104-12
97. Hviid A, Melbye M, Pasternak B. Use of selective serotonin reuptake inhibitors during pregnancy and risk of autism. N Engl J Med 2013;369:2406-15
98. Rai D, Lee BK, Dalman C, et al. Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based case-control study. BMJ 2013;346:f2059
99. Reis M, Kallen B. Combined use of selective serotonin reuptake inhibitors and sedatives/hypnotics during pregnancy: risk of relatively severe congenital malformations or cardiac defects. A register study. BMJ Open 2013;3:e002166. doi:10.1136/bmjopen 2012-002166
100. Kallen B, Reis M. Neonatal complications after maternal concomitant use of SSRI and other central nervous system active drugs during the second or third trimester of pregnancy. J Clin Psychopharmacol 2012;32:608-14
101. Health topics: breatfeeding. World Health Organisation. 2014. Available from: http://www.who. int/topics/breastfeeding/fr/ [Last accessed 4 July 2014]
102. Breastfeeding and the use of human milk. AAP Policy Statement. American Academy of Pediatrics. 2012. Available from: www.pediatrics. org/cgi/doi/10.1542/peds.2011-3552 [Last accessed 4 July 2014]
103. Gorman JR, Kao K, Chambers CD. Breastfeeding among women exposed to antidepressants during pregnancy. J Hum Lact 2012;28:181-8
104. Rubin ET, Lee A, Ito S. When breastfeeding mothers need CNS-acting drugs. Can J Clin Pharmacol 2004;11:e257-66
105. Belfort MB, Rifas-Shiman SL, Kleinman KP, et al. Infant feeding and childhood cognition at ages 3 and 7 years: effects of breastfeeding duration and exclusivity. JAMA Pediatr 2013;167:836-44
106. Gentile S. Drug treatment for mood disorders in pregnancy. Curr Opin Psychiatry 2011;24:34-40
107. Judd LL, Akiskal HS, Maser JD, et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 1998;50:97-108
108. Coverdale JH, McCullough LB, Chervenak FA. The ethics of randomized placebo-controlled trials of antidepressants with pregnant women: a systematic review. Obstet Gynecol 2008;112:1361-8
109. Palmsten K, Hernandez-Diaz S. Can nonrandomized studies on the safety of antidepressants during pregnancy convincingly beat confounding, chance, and prior beliefs? Epidemiology 2012;23:686-8
110. Dietz PM, Williams SB, Callaghan WM, et al. Clinically identified maternal depression before, during, and after pregnancies ending in live births. Am J Psychiatry 2007;164:1515-20
111. Gibson J, McKenzie-McHarg K, Shakespeare J, et al. A systematic review of studies validating the Edinburgh Postnatal Depression Scale in antepartum and postpartum women. Acta Psychiatr Scand 2009;119:350-64
112. Husain N, Rahman A, Husain M, et al. Detecting depression in pregnancy: validation of EPDS in British pakistani mothers. J Immigr Minor Health 2014;16(6):1085-92
113. Toreki A, Ando B, Kereszturi A, et al. The Edinburgh Postnatal Depression Scale: translation and antepartum validation for a Hungarian sample. Midwifery 2013;29:308-15
114. Rubertsson C, Borjesson K, Berglund A, et al. The Swedish validation of Edinburgh Postnatal Depression Scale (EPDS) during pregnancy. Nord J Psychiatry 2011;65:414-18
115. Bergink V, Kooistra L, Lambregtse-van den Berg MP, et al. Validation of the Edinburgh Depression Scale during pregnancy. J Psychosom Res 2011;70:385-9
116. Monk C, Spicer J, Champagne FA. Linking prenatal maternal adversity to developmental outcomes in infants: the role of epigenetic pathways. Dev Psychopathol 2012;24:1361-76
117. Nestler EJ. Epigenetic mechanisms of depression. JAMA Psychiatry 2014;71:454-6
118. Non AL, Binder AM, Kubzansky LD, Michels KB. Genome-wide DNA methylation in neonates exposed to maternal depression, anxiety, or SSRI medication during pregnancy. Epigenetics 2014;9
119. Spinelli MG, Endicott J, Leon AC, et al. A controlled clinical treatment trial of interpersonal psychotherapy for depressed pregnant women at 3 New York City sites. J Clin Psychiatry 2013;74:393-9
120. Grote NK, Swartz HA, Geibel SL, et al. A randomized controlled trial of culturally relevant, brief interpersonal psychotherapy for perinatal depression. Psychiatr Serv 2009;60:313-21
121. Kjaersgaard MI, Parner ET, Vestergaard M, et al. Prenatal antidepressant exposure and risk of spontaneous abortion - a population-based study. PLoS One 2013;8:e72095
122. LactMed database: national Library of Medicine. Available from: http://toxnet. nlm.nih.gov/cgi-bin/sis/htmlgen?LACT [Last accessed 16 July 2013]